0000000000252825

AUTHOR

Sara Tabbai

showing 2 related works from this author

Effects of the LPA1 Receptor Deficiency and Stress on the Hippocampal LPA Species in Mice

2019

Lysophosphatidic acid (LPA) is an important bioactive lipid species that functions in intracellular signaling through six characterized G protein-coupled receptors (LPA1-6). Among these receptors, LPA1 is a strong candidate to mediate the central effects of LPA on emotion and may be involved in promoting normal emotional behaviors. Alterations in this receptor may induce vulnerability to stress and predispose an individual to a psychopathological disease. In fact, mice lacking the LPA1 receptor exhibit emotional dysregulation and cognitive alterations in hippocampus-dependent tasks. Moreover, the loss of this receptor results in a phenotype of low resilience with dysfunctional coping in res…

0301 basic medicineElevated plus mazemedicine.medical_specialtyMALDI-TOFF mass spectrometry:Medicina Básica [Ciências Médicas]BiologyHippocampal formationemotionslcsh:RC321-57103 medical and health scienceschemistry.chemical_compoundstressCellular and Molecular Neuroscience0302 clinical medicineInternal medicineLysophosphatidic acidmedicineReceptorlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMolecular BiologyScience & TechnologyEmotional dysregulationmedicine.diseasePhenotypeLPA species030104 developmental biologyEndocrinologychemistryMood disordersCiências Médicas::Medicina Básicalipids (amino acids peptides and proteins)LPA receptor 1LPA1 receptorbiological phenomena cell phenomena and immunity030217 neurology & neurosurgeryIntracellularLPA(1) receptorFrontiers in Molecular Neuroscience
researchProduct

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

2022

Introduction: Idiosyncratic drug-induced liver injury (DILI) is a rare adverse reaction to drugs and other xenobiotics. DILI has different grades of severity and may lead to acute liver failure (ALF), for which there is no effective therapy. N-acetylcysteine (NAC) has been occasionally tested for the treatment of non-acetaminophen drug-induced ALF. However, limited evidence for its efficacy and safety is currently available. Our aim was to elucidate the benefit and safety of NAC in DILI and evaluate its hepatoprotective effect.Methods: We conducted a systematic review to evaluate the management and prevention focused on NAC in idiosyncratic DILI. The main outcomes included mortality due to …

PharmacologyPharmacology (medical)DILInon-acetaminophenacute liver failureacute liver injuryN-acetylcysteine
researchProduct